Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents. [electronic resource]
- Cancer science Jul 2015
- 902-8 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1349-7006
10.1111/cas.12679 doi
Antineoplastic Agents--pharmacology Cell Line, Tumor Cisplatin--pharmacology Drug Synergism Fanconi Anemia Complementation Group D2 Protein--metabolism Humans Lung Neoplasms Pentacyclic Triterpenes Proteasome Endopeptidase Complex--metabolism Protein Stability Proteolysis Triterpenes--pharmacology